Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids. Issue 1 (2nd September 2020)

• Record Type: Journal Article
• Authors: Amaral, Julio M.X.; Padilha, Monica C.; Chagas, Silvana V.; Baker, Julien S.; Mullen, Carrie; Vieira Neto, Leonardo; Aquino Neto, Francisco R.; Cruz, Marcelo S.
• Is Part Of: Drug testing and analysis. Volume 13:Issue 1(2021)
• Page Start: 197
• Page End: 202
• Publication Date: 2020-09-02
• Subjects: anabolic androgenic steroids -- androgens -- attempted suicide -- mass spectrometry -- performance‐enhancing drugs; Drugs -- Analysis -- Periodicals; Drug testing -- Periodicals; Chemistry, Forensic -- Periodicals; 615.1901
• DOI: 10.1002/dta.2912
• Languages: English
• ISSNs: 1942-7603

Abstract

Abstract: The treatment of a man who attempted suicide after experiencing symptoms of anxiety and aggressiveness associated with the use of androgenic‐anabolic steroids (AAS) is described. This report includes 30 days of inpatient treatment and a 6‐month follow‐up. Regular use of fluoxetine apparently prevented the onset of anxiety, depression, aggressiveness, and suicide ideation, even with the concurrent use of AAS. The urinary concentration of androgens, metabolites of AAS, and fluoxetine were monitored through analysis of urinary samples by the Brazilian Laboratory of Doping Control. Our results are congruent with previous findings describing the risk of suicide prompted by AAS use as well as the efficacy of fluoxetine in the treatment of mood disorders associated with the use of anabolic steroids. Abstract : A man who attempted suicide after the use of androgenic‐anabolic steroids (AAS) was treated with fluoxetine. This apparently prevented anxiety, depression, and suicide ideation, despite the concurrent use of AAS. Urinary concentrations of androgens and fluoxetine were monitored by the Brazilian Laboratory of Doping Control.